NCT01238042View on ClinicalTrials.gov

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

November 30, 2014

Conditions
Barrett's EsophagusCISHGD
Interventions
DRUG

HPPH

3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT01238042 - Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus | Biotech Hunter | Biotech Hunter